Wrap Text
Form 8-K current report
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
FORM 8-K CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, ASPI stockholders are advised
that a Form 8-K has been filed with the U.S. Securities and Exchange Commission.
Item 2.01. Completion of Acquisition or Disposition of Assets.
This Current Report on Form 8-K is being filed in connection with the completion, on January 6, 2026 (the
"Closing Date"), of the previously announced acquisition (the "Transaction") contemplated by the firm
intention letter agreement, dated May 20, 2025 (the "Agreement"), by and between ASP Isotopes Inc. (the
"Company" or "ASP Isotopes") and Renergen Limited, a public company incorporated under the laws of the
Republic of South Africa focused on production of liquefied helium (LHe) and liquefied natural gas (LNG)
("Renergen"), pursuant to which, subject to the terms and conditions thereof, ASP Isotopes acquired all of
the issued ordinary shares of Renergen ("Renergen Ordinary Shares"), in exchange for shares of ASP
Isotopes common stock, par value $0.01 per share (the "Company Common Stock"), through the
implementation of a scheme of arrangement (the "Scheme") in accordance with Sections 114 and 115 of
the South African Companies Act, No. 71 of 2008.
On the Closing Date, ASP Isotopes acquired all of the issued Renergen Ordinary Shares from Renergen
shareholders in exchange for shares of Company Common Stock at an exchange ratio of 0.09196 shares
of Company Common Stock for each Renergen Ordinary Share (the "Consideration Shares") through the
implementation of the Scheme, resulting in the issuance of an aggregate of 14,270,000 Consideration
Shares. Any entitlements to fractions of shares of Company Common Stock that otherwise would be
issuable pursuant to the Scheme were rounded to the nearest whole number of shares and a cash payment
was made for any fractional shares resulting from such rounding. As a result of the Transaction, Renergen
became a direct, wholly owned subsidiary of ASP Isotopes.
In connection with the Transaction, Renergen Ordinary Shares will be delisted from the Johannesburg
Stock Exchange (the "JSE"), the Australian Securities Exchange and A2X. The Company Common Stock
continues to be listed on The Nasdaq Global Market and on the JSE.
In addition, on the Closing Date, Stefano Marani, the Chief Executive Officer of Renergen, has been
appointed as the President, Electronics and Space, of the Company, and Nick Mitchell, the Chief Operating
Officer of Renergen, has been appointed Co-Chief Operating Officer of the Company.
The foregoing description of the Agreement and the Transaction does not purport to be complete and is
qualified in its entirety by reference to the full text of the Agreement and the Joint Firm Intention
Announcement, dated May 20, 2025, announcing the execution of the Agreement and the Transaction,
which are incorporated herein by reference to Exhibit 2.1 and Exhibit 99.3, respectively, to the Company's
Current Report on Form 8-K filed with the SEC on May 20, 2025.
Item 3.02. Unregistered Sales of Equity Securities.
The information provided in Item 2.01 of this Current Report on Form 8-K is incorporated by reference into
this Item 3.02. The issuance of Consideration Shares described above was exempt from registration under
the Securities Act of 1933, as amended (the "Securities Act"), in reliance on Rule 802 promulgated under
the Securities Act. At the commencement of the Transaction, Renergen was a "foreign private issuer," as
that term is defined in Rule 405 under the Securities Act, and U.S. shareholders held less than 10% of the
issued Renergen Ordinary Shares. U.S. holders of Renergen Ordinary Shares were permitted to participate
in the Transaction on terms at least as favorable as those offered in any other jurisdiction. All informational
documents provided to Renergen shareholders in connection with the Transaction were furnished, in
English, to the SEC on Form CB by the first business day after publication or dissemination and were
disseminated, in English, to U.S. shareholders on a comparable basis to that provided to shareholders in
South Africa. Any information relating to the Transaction that Renergen or the Company has disseminated
to stockholders located outside the U.S. has been disseminated in the U.S. in a manner reasonably
calculated to inform U.S. holders of the offer. Finally, the legend required by Rule 802(b) under the
Securities Act has been included as required in the informational documents regarding the Transaction
disseminated to U.S. holders.
Item 8.01. Other Events.
On January 7, 2026, the Company issued a press release announcing the completion of the Transaction.
The full text of the press release, a copy of which is attached hereto as Exhibit 99.2, is incorporated herein
by reference.
Forward-Looking Statements
This document contains "forward-looking statements" within the meaning of the safe harbor provisions of
the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by
words like "may," "will," "likely," "should," "expect," "anticipate," "future," "plan," "believe," "intend," "goal,"
"seek," "estimate," "project," "continue," and variations of such words and similar expressions. These
forward-looking statements are not guarantees of future performance and involve risks, assumptions, and
uncertainties, including, but not limited to, risks related to: (i) integration of the Company's and Renergen's
businesses and the ability to recognize the anticipated synergies and benefits of the Transaction; (ii)
disruption from the acquisition of Renergen making it more difficult to maintain business and operational
relationships; (iii) the negative effects of the Transaction on the market price of the Company's securities;
(iv) significant transaction costs and unknown liabilities; (v) litigation or regulatory actions related to the
acquisition of Renergen; (vi) the Company's inability to adequately protect its intellectual property; (vii) the
Company's inability to manage growth; and (viii) such other factors as are set forth in the periodic reports
filed by the Company with the U.S. Securities and Exchange Commission (the "SEC"), including but not
limited to those described under the heading "Risk Factors" in its annual reports on Form 10-K, quarterly
reports on Form 10-Q and any other filings made with the SEC from time to time, which are available via
the SEC's website at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual results may vary materially from those indicated or
anticipated by these forward-looking statements. Therefore, you should not rely on any of these forward-
looking statements.
The forward-looking statements included in this report are made only as of the date of this report, and
except as otherwise required by applicable securities law, the Company assumes no obligation, nor does
the Company intend to publicly update or revise any forward-looking statements to reflect subsequent
events or circumstances.
Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Businesses or Funds Acquired.
The financial statements required by Item 9.01(a) of Form 8-K are not included in this Current Report.
The Company intends to file these financial statements by amendment within the timeframe permitted
by Item 9.01(a).
(b) Pro Forma Financial Information.
The pro forma financial information required by Item 9.01(b) of Form 8-K is not included in this Current
Report. The Company intends to file this pro forma information by amendment within the timeframe
permitted by Item 9.01(b).
A copy of the Form 8-K can also be found at: Inline Viewer: ASP Isotopes Inc. 8-K 2026-01-06
The Company has a primary listing on the Nasdaq and a secondary listing on the Main Board of the JSE.
7 January 2026
Sponsor
Valeo Capital Proprietary Limited
Date: 07-01-2026 05:05:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
